Q4 and FY 2023 presentation and Q&A
How does this Q&A work:
This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.
The company will address as many questions as possible, and focus on those questions most wanted by investors.
Speakers at this event:
8 Questions
Feb. 28, 2024
When are the phase 3 trials expected to be finished, and when will there be a product available that you will be able to sell?
how do you expect that the trpv-1 antagonist will compete with other similar drugs?
Feb. 23, 2024
Pila Pharma is positioned in a interesting field, but with some really big competitors that is further and already has an establish market position. Are you worried that you will be late to the party looking at the years of development in front of you?
Feb. 27, 2024
We've seen a lot of acquisitions in the diabetes and obesity segment lately, mostly from companies acquiring GLP-1 agonists looking to join the party, but also some of the established players buying early-stage project with very different mechanisms of action - presumably to combine with their GLP-1's.
Do you think something similar could happen to Pila? When would you be a target for acquisition?
Feb. 27, 2024
Hi Dorte,
For sure its tough times for any biotech company that does not generate revenue.
Frustrating for early investors, but timing has not been with you in the sense of the market downturn and inflation that hit after COVID.
How do you see the curve changing for the PILA stock to once again point and rise upwards?
What would be the drivers for an upward trajectory? Would it be to perform well on weight / CVD?
Feb. 27, 2024
Dorte, there has been a lot of questions regarding the side effects of the new peptide treatments like semaglutide which seem to be mostly gastrointestinal. Of course with treatment intended to for life, it seems quite unattractive regardless of weight-loss to look into chronic diarrhoea or constipation for example.
TRPV1 antagonists generally seems to mostly have had issues with temperature in the past and perhaps sensation of pain.
What are the main side effects of your treatment? What have you seen in your clinical trials?
Would you say side effects could actually constitute beneficial effects?
Feb. 27, 2024
Dear Pila, Can you provide us all with an updated timeline for 2024-2025 please
Feb. 23, 2024
When could we expect to receive some data on the efficacy of the pill in obesity, not just the safety and toleration of the pill but how big of an impact it can have in obesity? And are you aiming to beat products like Wegovy in efficacy or is this unrealistic?
Feb. 23, 2024
How will you tackle the competition in the field. Are you looking to go up against companies like Novo Nordisk and Eli Lily or are you looking to partner with them or a third player in the market during development for financing and speeding up the process and when would it be beneficial to establish such a partnership?